Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 6/20 | 1.00 |
| ▸ | EZH1 | Q92800 | 5/20 | 1.00 |
| ▸ | EED | O75530 | 3/20 | 1.00 |
| ▸ | RBBP4 | Q09028 | 3/20 | 1.00 |
| ▸ | SUZ12 | Q15022 | 3/20 | 1.00 |
| ▸ | RBBP7 | Q16576 | 3/20 | 1.00 |
| ▸ | AEBP2 | Q6ZN18 | 2/20 | 1.00 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.84 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.84 |
| ▸ | HDAC6 | Q9UBN7 | 13/20 | 0.81 |
| ▸ | HDAC1 | Q13547 | 10/20 | 0.81 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.81 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.81 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.81 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.81 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.81 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.81 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.81 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29397460 | 1.00 | EZH2 (1.00) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL21271616 | 0.94 | EZH2 (1.00) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL31505792 | 0.94 | EZH2 (1.00) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL2595231 | 0.94 | EZH1 (0.91) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL12180851 | 0.93 | EZH2 (0.88) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL21284996 | 0.92 | EZH2 (0.86) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL12180703 | 0.92 | EZH2 (0.85) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL21285037 | 0.92 | EZH2 (0.85) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL21271702 | 0.92 | EZH2 (0.85) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL12180659 | 0.92 | EZH1 (1.00) | EZH2EZH1EEDRBBP4SUZ12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2908843-B1 | TREATING CANCER | AGENCY SCIENCE TECH & RES (SG) | 2019-09-04 | — | — | EP | claimed |
| US-9889180-B2 | Method of treating cancer | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-02-13 | — | — | US | claimed |
| US-20150258175-A1 | METHOD OF TREATING CANCER | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-09-17 | — | — | US | claimed |
| EP-2908843-A1 | METHOD OF TREATING CANCER | Agency For Science, Technology And Research (SG) | 2015-08-26 | — | — | EP | claimed |
| EP-2566328-B1 | INDAZOLES | GLAXOSMITHKLINE LLC (US) | 2015-03-04 | — | — | EP | claimed |
| US-8846935-B2 | Indazoles | GLAXOSMITHKLINE LLC (US) | 2014-09-30 | — | — | US | claimed |
| WO-2014077784-A1 | METHOD OF TREATING CANCER | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2014-05-22 | — | — | WO | claimed |
| EP-2566328-A1 | INDAZOLES | GlaxoSmithKline LLC (US) | 2013-03-13 | — | — | EP | claimed |
| US-20130053383-A1 | INDAZOLES | GLAXOSMITHKLINE LLC | 2013-02-28 | — | — | US | claimed |
| WO-2011140325-A1 | INDAZOLES | GLAXOSMITHKLINE LLC (US) | 2011-11-10 | — | — | WO | claimed |
| EP-2908843-B1 | TREATING CANCER | AGENCY SCIENCE TECH & RES (SG) | 2019-09-04 | — | — | EP | disclosed |
| US-9889180-B2 | Method of treating cancer | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-02-13 | — | — | US | disclosed |
| US-20150258175-A1 | METHOD OF TREATING CANCER | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-09-17 | — | — | US | disclosed |
| EP-2908843-A1 | METHOD OF TREATING CANCER | Agency For Science, Technology And Research (SG) | 2015-08-26 | — | — | EP | disclosed |
| US-9018382-B2 | Indazoles | GLAXOSMITHKLINE LLC (US) | 2015-04-28 | — | — | US | disclosed |
| WO-2014077784-A1 | METHOD OF TREATING CANCER | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2014-05-22 | — | — | WO | disclosed |
| US-20130053383-A1 | INDAZOLES | GLAXOSMITHKLINE LLC | 2013-02-28 | — | — | US | disclosed |
| US-20130053383-A1 | INDAZOLES | GLAXOSMITHKLINE LLC | 2013-02-28 | — | — | US | disclosed |
| US-20130053383-A1 | INDAZOLES | GLAXOSMITHKLINE LLC | 2013-02-28 | — | — | US | disclosed |
| WO-2011140325-A1 | INDAZOLES | GLAXOSMITHKLINE LLC (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053383-A1 | INDAZOLES | IDH3A, CYP3A7, IDH3B | EZH2 1599/4885EZH1 1398/4885EED 3742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.